Gerhard Schmitz - Merck Head Accounting

MRK Stock  EUR 155.35  1.45  0.94%   

Insider

Gerhard Schmitz is Head Accounting of Merck Company
Age 60
Phone49 6151 72 0
Webhttps://www.merckgroup.com

Merck Management Efficiency

The company has return on total asset (ROA) of 0.0656 % which means that it generated a profit of $0.0656 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1422 %, meaning that it generated $0.1422 on every $100 dollars invested by stockholders. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 7.93 B in total debt with debt to equity ratio (D/E) of 0.65, which is about average as compared to similar companies. Merck Company has a current ratio of 0.98, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Merck until it has trouble settling it off, either with new capital or with free cash flow. So, Merck's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Merck Company sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Merck to invest in growth at high rates of return. When we think about Merck's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

David UrbanekElanco Animal Health
56
Chunhua ZhongHANSOH PHARMAC HD 00001
44
Min HuHANSOH PHARMAC HD 00001
42
Ramiro CabralElanco Animal Health
51
Ash RajendraSuperior Plus Corp
N/A
Yasheng YangOrigin Agritech
51
Larbi LierElanco Animal Health
N/A
Chuanhe XuHANSOH PHARMAC HD 00001
55
Gongzheng WuHANSOH PHARMAC HD 00001
48
Aifeng LyuHANSOH PHARMAC HD 00001
42
Marcela KirbergerElanco Animal Health
56
Manfred MuellerIdentiv
53
Sheung ChanHANSOH PHARMAC HD 00001
65
Yuan SunHANSOH PHARMAC HD 00001
32
David RicksElanco Animal Health
50
Justin ScarpullaIdentiv
50
Chris KeeleyElanco Animal Health
N/A
Cuifang MaHANSOH PHARMAC HD 00001
43
Denise ScotsKnightElanco Animal Health
59
Amir KhoshniyatiIdentiv
N/A
Harry KanwarSuperior Plus Corp
N/A
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. MERCK Kommanditgesellschaft auf Aktien operates as a subsidiary of E. MERCK KGAA operates under Drug ManufacturersSpecialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 57850 people. Merck Company (MRK) is traded on Frankfurt Exchange in Germany and employs 63,723 people.

Management Performance

Merck Company Leadership Team

Elected by the shareholders, the Merck's board of directors comprises two types of representatives: Merck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck's management team and ensure that shareholders' interests are well served. Merck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck's outside directors are responsible for providing unbiased perspectives on the board's policies.
Thomas Glocer, Independent Director
Matthias Heinzel, CEO Board
Jennifer Zachary, Executive Vice President, General Counsel, Corporate Secretary
Gerhard Schmitz, Head Accounting
Christine Seidman, Independent Director
Kathy Warden, Independent Director
Constantin Fest, Head Relations
Paul Rothman, Independent Director
Mary Coe, Independent Director
Michael Fleming, Senior Vice President Chief Ethics and Compliance Officer
Peter Guenter, CEO Board
Barbara Weiland, Chief Officer
Belen MD, Chair CEO
Marcus Kuhnert, CFO Board
Peter Wendell, Independent Director
Friederike Rotsch, Group Compliance
Leslie Brun, Lead Independent Director
Julie Gerberding, Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health
Inge Thulin, Independent Director
Dirk Toepfer, Chief Officer
Pamela Craig, Independent Director
Patricia Russo, Independent Director
Franklin Clyburn, Executive Vice President Chief Commercial Officer
Rita Karachun, Senior Vice President - Finance, Global Controller
Dean Li, Executive Vice President and Presidentident, Merck Research Laboratories
Kai Beckmann, CEO Board
Robert Davis, Executive Vice President, Global Services, Chief Financial Officer
Thomas Cech, Independent Director
Michael Nally, Executive Vice President, Chief Marketing Officer
Roger Perlmutter, Executive Vice President and Presidentident - Merck Research Laboratories
Steven Mizell, Executive Vice President, Chief Human Resources Officer, Human Resources
Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division
Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health
Kenneth Frazier, Chairman of the Board, President, Chief Executive Officer

Merck Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Merck in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Merck's short interest history, or implied volatility extrapolated from Merck options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Merck Company is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merck Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merck Company Stock. Highlighted below are key reports to facilitate an investment decision about Merck Company Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Complementary Tools for Merck Stock analysis

When running Merck's price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
CEOs Directory
Screen CEOs from public companies around the world
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.